NCT04667910 is a Phase 2 clinical trial of 601 1.25mg in Central Retinal Vein Occlusion, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd..

Who is sponsoring NCT04667910?

NCT04667910 is sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd..

What drugs are being tested in NCT04667910?

Interventions in NCT04667910: 601 1.25mg, Ranibizuman 0.5 mg.

What condition does NCT04667910 study?

NCT04667910 studies Central Retinal Vein Occlusion.

Is NCT04667910 still recruiting?

NCT04667910 is currently completed. Last updated 27 June 2025.

Last reviewed 2025-06-27 · How we verify

NCT04667910

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

Completed Phase 2 Last updated 27 June 2025

What this trial tests

Phase 2 trial testing 601 1.25mg in Central Retinal Vein Occlusion in 60 participants. Completed in 16 November 2022.

Timeline

27 January 2021

Primary endpoint
16 November 2022

16 November 2022

Quick facts

Lead sponsor	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	27 January 2021
Primary completion	16 November 2022
Estimated completion	16 November 2022
Sites	1 location across China

Drugs / interventions tested

601 1.25mg — full drug profile →
Ranibizuman 0.5 mg — full drug profile →

Conditions studied

Central Retinal Vein Occlusion — all drugs for Central Retinal Vein Occlusion →

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Central Retinal Vein Occlusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to CRVO

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials.
Zhao S, Wu M, Zhong J, Chen B, et al · · 2025 · PMID 41448868 · DOI 10.1136/bjo-2025-327845

Verify or expand the search:

Other trials of 601 1.25mg

Trials testing the same drug.

NCT05520177 — A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss · Phase 3 · completed
NCT04667897 — 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO) · Phase 2 · completed

Other recruiting trials for Central Retinal Vein Occlusion

Currently open trials in the same condition.

NCT05476926 — A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products · active not recruiting

Other Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. trials

Trials by the same sponsor.

NCT07507513 — The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC · Phase 2 · not yet recruiting
NCT07349329 — A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) · Phase 3 · not yet recruiting
NCT07261644 — A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) · Phase 3 · recruiting
NCT07185269 — The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE · Phase 1, PHASE2 · recruiting
NCT07042126 — Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04667910 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Last refreshed: 27 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04667910.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing